- Home
- TONX vs AARD Comparison
TONX vs AARD Comparison
Compare TONX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TONX
- AARD
- Stock Information
- Founded
- TONX N/A
- AARD 2017
- Country
- TONX United States
- AARD United States
- Employees
- TONX N/A
- AARD N/A
- Industry
- TONX Other Consumer Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- TONX Consumer Discretionary
- AARD Health Care
- Exchange
- TONX Nasdaq
- AARD Nasdaq
- Market Cap
- TONX 248.4M
- AARD 277.9M
- IPO Year
- TONX N/A
- AARD 2025
- Fundamental
- Price
- TONX $3.93
- AARD $11.22
- Analyst Decision
- TONX
- AARD Strong Buy
- Analyst Count
- TONX 0
- AARD 7
- Target Price
- TONX N/A
- AARD $31.43
- AVG Volume (30 Days)
- TONX 874.2K
- AARD 151.9K
- Earning Date
- TONX 11-14-2025
- AARD 11-14-2025
- Dividend Yield
- TONX N/A
- AARD N/A
- EPS Growth
- TONX N/A
- AARD N/A
- EPS
- TONX N/A
- AARD N/A
- Revenue
- TONX $4,279,000.00
- AARD N/A
- Revenue This Year
- TONX $526.82
- AARD N/A
- Revenue Next Year
- TONX $45.45
- AARD N/A
- P/E Ratio
- TONX N/A
- AARD N/A
- Revenue Growth
- TONX 4095.10
- AARD N/A
- 52 Week Low
- TONX $3.46
- AARD $4.88
- 52 Week High
- TONX $13.90
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- TONX N/A
- AARD 39.08
- Support Level
- TONX N/A
- AARD $10.65
- Resistance Level
- TONX N/A
- AARD $17.94
- Average True Range (ATR)
- TONX 0.00
- AARD 0.95
- MACD
- TONX 0.00
- AARD -0.64
- Stochastic Oscillator
- TONX 0.00
- AARD 7.82
About TONX TON Strategy Company Common Stock
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.